| Code | 2526D | ||||||||||
| MA number | 44/0296/19-S | ||||||||||
| Product Form: | tbl flm 60x50 mg (blis.OPA/Al/PVC/Al) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Zentiva, k.s., Czechia | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 30.09.2019 |
| Pediatric indication: | Yes |
| Pediatric posology: | Yes |
| Pediatric warnings: | Yes |
| SPC: |
SPC_Dasatinib Zentiva 50 mg filmom obalené tablety_12.2022.pdf
|
| PIL: |
PIL_Dasatinib Zentiva 50 mg filmom obalené tablety_12.2022.pdf
|
| Safety feature | Yes |
| Data update: | 15.02.2024 |
